Recently, Wang et al. [126] reported that the viabilities of prostate cancer cells increased upon treatment with conditioned media from EREG-overexpressing prostate stromal cells and that treatment with an anti-EREG monoclonal antibody reduced this effect. The gene discussed is EREG; the disease is prostate carcinoma.